Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: A case series and literature review

Cancer Gene Therapy

Volumn 19, Issue 9, 2012, Pages 593-600

  Zarogoulidis, P ^a   Chatzaki, E ^b   Hohenforst Schmidt, W ^c   Goldberg, E P ^d   Galaktidou, G ^e   Kontakiotis, T ^a   Karamanos, N ^f   Zarogoulidis, K ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d University of Florida   (United States)

^e Theagen Anticancer Institute Research Laboratory   (Greece)

^f UNIVERSITY OF PATRAS   (Greece)

Author keywords

augmentation; bystander effect; lung cancer; suicide gene therapy

Indexed keywords

ADENOVIRUS VECTOR; CARBOPLATIN; CYTOSINE DEAMINASE; DOCETAXEL; ETOPOSIDE; FLUCYTOSINE; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; BYSTANDER EFFECT; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG POTENTIATION; ELECTRON MICROSCOPY; FEVER; FLU LIKE SYNDROME; HUMAN; LEWIS CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; PLEURA EFFUSION; PLEURA FLUID; PRIORITY JOURNAL; REVIEW; SUICIDE GENE THERAPY; TREATMENT OUTCOME; TUMOR REGRESSION; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE;

ADENOVIRIDAE; AGED; ANEMIA; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BYSTANDER EFFECT; CARCINOMA, NON-SMALL-CELL LUNG; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEUTROPENIA; PLEURAL EFFUSION, MALIGNANT; PRODRUGS; PROPORTIONAL HAZARDS MODELS; SMALL CELL LUNG CARCINOMA; TOMOGRAPHY, X-RAY COMPUTED;

ANIMALIA;

EID: 84865234695     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.36     Document Type: Review

References (74)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Ready NE, Dudek AZ, Pang HH, Hodgson LD, Graziano SL, Green MR et al. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol 2011; 29: 4436-4441.
3. Hosomi Y, Shibuya M, Niho S, Ichinose Y, Kiura K, Sakai H et al. Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer. Anticancer Res 2011; 31: 3449-3456.
4. Hunter TB, Manimala NJ, Luddy KA, Catlin T, Antonia SJ. Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF. Anticancer Res 2011; 31: 3193-3204.
5. Langer C, Li S, Schiller J, Tester W, Rapoport BL, Johnson DH. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol 2007; 25: 418-423.
6. Curran Jr WJ, Schiller JH, Wolkin AC, Comis RL. Addressing the current challenges of non-small-cell lung cancer clinical trial accrual. Clin Lung Cancer 2008; 9: 222-226.
7. Somer RA, Sherman E, Langer CJ. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599. Clin Lung Cancer 2008; 9: 102-105.
8. Novello S, Longo M, Levra MG. Toward therapies tailored to patient characteristics. J Thorac Oncol 2007; 2(5 Suppl): S38-S41.
9. Kashkin KN, Musatkina EA, Komelkov AV, Tonevitsky EA, Sakharov DA, Vinogradova TV et al. Genes potentially associated with cisplatin resistance of lung cancer cells. Dokl Biochem Biophys 2011; 438: 147-150.
10. Tschopp JM, Schnyder JM, Astoul P, Noppen M, Froudarakis M, Bolliger CT et al. Pleurodesis by talc poudrage under simple medical thoracoscopy: an international opinion. Thorax 2009; 64: 273-274; author reply 274.
11. Froudarakis ME, Noppen M. Medical thoracoscopy: new tricks for an old trade. Respiration 2009; 78: 373-374.
12. Balassoulis G, Sichletidis L, Spyratos D, Chloros D, Zarogoulidis K, Kontakiotis T et al. Efficacy and safety of erythromycin as sclerosing agent in patients with recurrent malignant pleural effusion. Am J Clin Oncol 2008; 31: 384-389.
13. Qian Q, Zhan P, Sun WK, Zhang Y, Song Y, Yu LK. Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control. Neoplasma 2012; 59: 433-439.
14. Christensen CL, Gjetting T, Poulsen TT, Cramer F, Roth JA, Poulsen HS. Targeted cytosine deaminase-uracil phosphoribosyl transferase suicide gene therapy induces small cell lung cancer-specific cytotoxicity and tumor growth delay. Clin Cancer Res 2010; 16: 2308-2319.
15. Markman M, Cleary S, Pfeifle C, Howell SB. Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma. Cancer 1986; 58: 18-21.
16. Markman M. Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer. Gynecol Oncol 2010; 117: 390; author reply 391.
17. Zarogoulidis P, Eleftheriadou E, Sapardanis I, Zarogoulidou V, Lithoxopoulou H, Kontakiotis T et al. Feasibility and effectiveness of inhaled carboplatin in NSCLC patients. Invest New Drugs advance online publication, 8 July 2011 (e-pub ahead of print).
18. Garcia-Sanchez F, Pizzorno G, Fu SQ, Nanakorn T, Krause DS, Liang J et al. Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation. Blood 1998; 92: 672-682.
19. Liu Y, Ye T, Maynard J, Akbulut H, Deisseroth A. Engineering conditionally replication-competent adenoviral vectors carrying the cytosine deaminase gene increases the infectivity and therapeutic effect for breast cancer gene therapy. Cancer Gene Ther 2006; 13: 346-356.
20. Liu Y, Deisseroth A. Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy. Cancer Gene Ther 2006; 13: 845-855.
21. Akbulut H, Zhang L, Tang Y, Deisseroth A. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon. Cancer Gene Ther 2003; 10: 388-395.
22. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
23. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 1992; 89: 33-37.
24. Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 1993; 53: 83-88.
25. Ramesh R, Marrogi AJ, Munshi A, Abboud CN, Freeman SM. In vivo analysis of the 'bystander effect': a cytokine cascade. Exp Hematol 1996; 24: 829-838.
26. Freeman SM, Whartenby KA, Freeman JL, Abboud CN, Marrogi AJ. In situ use of suicide genes for cancer therapy. Semin Oncol 1996; 23: 31-45.
27. Kuriyama S, Masui K, Sakamoto T, Nakatani T, Kikukawa M, Tsujinoue H et al. Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil. Anticancer Res 1998; 18(5A): 3399-3406.
28. Zhong Z, Wan Y, Shi S, Han J, Zhang Z, Sun X. Co-delivery of adenovirus and carmustine by anionic liposomes with synergistic anti-tumor effects. Pharm Res 2012; 29: 145-157.
29. Saito A, Morishita N, Mitsuoka C, Kitajima S, Hamada K, Lee KM et al. Intravenous injection of irradiated tumor cell vaccine carrying oncolytic adenovirus suppressed the growth of multiple lung tumors in a mouse squamous cell carcinoma model. J Gene Med 2011; 13: 353-361.
30. Zhu Y, Lv H, Xie Y, Sheng W, Xiang J, Yang J. Enhanced tumor suppression by an ING4/IL-24 bicistronic adenovirus-mediated gene cotransfer in human non-small cell lung cancer cells. Cancer Gene Ther 2011; 18: 627-636.
31. Zhu Y, Farina JB, Meshack S, Santoveña A, Patel S, Oliva A et al. Anti-tumor effects of adenovirus containing human growth hormone sequences in a mouse model of human ovarian cancer. Endocrine 2010; 37: 430-439.
32. Peng XY, Won JH, Rutherford T, Fujii T, Zelterman D, Pizzorno G et al. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. Cancer Res 2001; 61: 4405-4413.
33. Graham FL, Prevec L. Manipulation of adenovirus vectors. Methods Mol Biol 1991; 7: 109-128.
34. Tsao AS, Garland L, Redman M, Kernstine K, Gandara D, Marom EM. A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. J Thorac Oncol 2011; 6: 598-601.
35. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice. ICH Secretariat: IFPMA, Geneva, Switzerland. J Postgrad Med 2001; 47: 199-203.
36. Xu Y, Liu Z, Kong H, Sun W, Liao Z, Zhou F et al. Co-expression of interleukin 12 enhances antitumor effects of a novel chimeric promoter-mediated suicide gene therapy in an immunocompetent mouse model. Biochem Biophys Res Commun 2011; 412: 763-768.
37. Wang ZX, Lu BB, Yang JS, Wang KM, De W. Adenovirus-mediated siRNA targeting c-Met inhibits proliferation and invasion of small-cell lung cancer (SCLC) cells. J Surg Res 2011; 171: 127-135.
38. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
39. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
40. Ohwada A, Hirschowitz EA, Crystal RG. Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver. Hum Gene Ther 1996; 7: 1567-1576.
41. Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19: 289-298.
42. Zhang J, Wei F, Wang H, Li H, Qiu W, Ren P et al. A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors. Cancer Biother Radiopharm 2010; 25: 487-495.
43. Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007; 13(15 Part 1): 4456-4466.
44. Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 2010; 18: 852-860.
45. Dong M, Li X, Hong LJ, Xie R, Zhao HL, Li K et al. Advanced malignant pleural or peritoneal effusion in patients treated with recombinant adenovirus p53 injection plus cisplatin. J Int Med Res 2008; 36: 1273-1278.
46. Margaris KN, Black RA. Modelling the lymphatic system: challenges and opportunities. J R Soc Interface 2012; 9: 601-612.
47. Kleinstreuer C, Zhang Z, Donohue JF. Targeted drug-aerosol delivery in the human respiratory system. Annu Rev Biomed Eng 2008; 10: 195-220.
48. Tatsumura T, Koyama S, Tsujimoto M, Kitagawa M, Kagamimori S. Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical. Br J Cancer 1993; 68: 1146-1149.
49. Zhao WZ, Wang JK, Li W, Zhang XL. [Clinical research on recombinant human Ad-p53 injection combined with cisplatin in treatment of malignant pleural effusion induced by lung cancer]. Ai zheng ¼Aizheng ¼ Chinese Journal of Cancer 2009; 28: 1324-1327.
50. Schwarzenberger P, Harrison L, Weinacker A, Marrogi A, Byrne P, Ramesh R et al. The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study. Hum Gene Ther 1998; 9: 2641-2649.
51. Watanabe Y, Kojima T, Kagawa S, Uno F, Hashimoto Y, Kyo S et al. A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy. Oncogene 2010; 29: 1145-1154.
52. Batra RK, Olsen JC, Hoganson DK, Caterson B, Boucher RC. Retroviral gene transfer is inhibited by chondroitin sulfate proteoglycans/glycosaminoglycans in malignant pleural effusions. J Biol Chem 1997; 272: 11736-11743.
53. Batra RK, Dubinett SM, Henkle BW, Sharma S, Gardner BK. Adenoviral gene transfer is inhibited by soluble factors in malignant pleural effusions. Am J Respir Cell Mol Biol 2000; 22: 613-619.
54. Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 1996; 14: 1574-1578.
55. Otake K, Ennist DL, Harrod K, Trapnell BC. Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. Hum Gene Ther 1998; 9: 2207-2222.
56. Mack CA, Song WR, Carpenter H, Wickham TJ, Kovesdi I, Harvey BG et al. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 1997; 8: 99-109.
57. Kay MA, Meuse L, Gown AM, Linsley P, Hollenbaugh D, Aruffo A et al. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci USA 1997; 94: 4686-4691.
58. Jooss K, Yang Y, Wilson JM. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther 1996; 7: 1555-1566.
59. Parks RJ, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996; 93: 13565-13570.
60. Mitani K, Graham FL, Caskey CT, Kochanek S. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci USA 1995; 92: 3854-3858.
61. Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004; 11: 351-357.
62. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Béthune MP et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003; 77: 8263-8271.
63. Zaiss AK, Machado HB, Herschman HR. The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem 2009; 108: 778-790.
64. Glasgow JN, Mikheeva G, Krasnykh V, Curiel DT. A strategy for adenovirus vector targeting with a secreted single chain antibody. PLoS One 2009; 4: e8355.
65. Eto Y, Yoshioka Y, Ishida T, Yao X, Morishige T, Narimatsu S et al. Optimized PEGylated adenovirus vector reduces the anti-vector humoral immune response against adenovirus and induces a therapeutic effect against metastatic lung cancer. Biol Pharm Bull 2010; 33: 1540-1544.
66. Eto Y, Yoshioka Y, Mukai Y, Okada N, Nakagawa S. Development of PEGylated adenovirus vector with targeting ligand. Int J Pharm 2008; 354: 3-8.
67. Hofherr SE, Shashkova EV, Weaver EA, Khare R, Barry MA. Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther 2008; 16: 1276-1282.
68. Kreppel F, Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther 2008; 16: 16-29.
69. Brunetti-Pierri N, Stapleton GE, Palmer DJ, Zuo Y, Mane VP, Finegold MJ et al. Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into nonhuman primates for liver-directed gene therapy. Mol Ther 2007; 15: 732-740.
70. Seregin SS, Appledorn DM, McBride AJ, Schuldt NJ, Aldhamen YA, Voss T et al. Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. Mol Ther 2009; 17: 685-696.
71. Peruzzi D, Dharmapuri S, Cirillo A, Bruni BE, Nicosia A, Cortese R et al. A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines. Vaccine 2009; 27: 1293-1300.
72. Sack BK, Herzog RW. Evading the immune response upon in vivo gene therapy with viral vectors. Curr Opin Mol Ther 2009; 11: 493-503.
73. Fridlender ZG, Sun J, Singhal S, Kapoor V, Cheng G, Suzuki E et al. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther 2010; 18: 1947-1959.
74. Jooss K, Chirmule N. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Ther 2003; 10: 955-963.